Does LORLATINIB Cause Second primary malignancy? 37 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 37 reports of Second primary malignancy have been filed in association with LORLATINIB (Lorbrena). This represents 0.7% of all adverse event reports for LORLATINIB.
37
Reports of Second primary malignancy with LORLATINIB
0.7%
of all LORLATINIB reports
5
Deaths
7
Hospitalizations
How Dangerous Is Second primary malignancy From LORLATINIB?
Of the 37 reports, 5 (13.5%) resulted in death, 7 (18.9%) required hospitalization, and 2 (5.4%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LORLATINIB. However, 37 reports have been filed with the FAERS database.
What Other Side Effects Does LORLATINIB Cause?
Death (1,050)
Neoplasm progression (633)
Off label use (394)
Weight increased (306)
Hallucination (290)
Blood cholesterol increased (281)
Dyspnoea (223)
Oedema peripheral (198)
Oedema (195)
Fatigue (188)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which LORLATINIB Alternatives Have Lower Second primary malignancy Risk?
LORLATINIB vs LORMETAZEPAM
LORLATINIB vs LORNOXICAM
LORLATINIB vs LOSARTAN
LORLATINIB vs LOSARTAN\LOSARTAN
LORLATINIB vs LOTEPREDNOL ETABONATE